10 March 2022 - Byooviz becomes the first Lucentis biosimilar to be approved in Canada following its approval in Europe and the United States in 2021.

Samsung Bioepis and Biogen Canada today announced that Health Canada has approved Byooviz – a biosimilar referencing Lucentis (ranibizumab) – for the treatment of neovascular (wet) age-related macular degeneration; visual impairment due to diabetic macular oedema, macular oedema secondary to retinal vein occlusion, choroidal neovascularisation secondary to pathologic myopia and choroidal neovascularisation secondary to ocular conditions other than age-related macular degeneration or pathologic myopia, including but not limited to angioid streaks, post-inflammatory retinochoroidopathy, central serous choriorentinopathy or idiopathic chorioretinaopathy.

Read Samsung Bioepis press release